Previous 10 | Next 10 |
Homology Medicines (NASDAQ:FIXX) -25% on FDA clinical hold for phenylketonuria trial. Karyopharm Therapeutics (NASDAQ:KPTI) -23% as medical chief steps down. Inspirato (NASDAQ:ISPO) -17%. QIWI (NASDAQ:QIWI) -14%. Yandex (NASDAQ:YNDX) -13%. Energy Vault (NYSE:NRGV) -12%. Ar...
The clinical-stage biopharmaceutical company Adagio Therapeutics (NASDAQ:ADGI) has lost ~6% in the premarket on Tuesday after the company announced the resignation of its Chief Executive Officer Tillman Gerngross. With the departure of Dr. Gerngross, Adagio’s (ADGI) board of ...
Multiple Initiatives Undertaken for ADG20 Assessment, Including Analysis of Clinical Data at 300mg Dose and Exploring Higher Doses of ADG20 in the Clinic Company Pursuing Portfolio of Antibodies in Response to Continuously Emerging SARS-CoV-2 Variants WALTHAM, Mass., Feb. ...
WALTHAM, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a C...
Agios Pharmaceuticals (AGIO -6.1%) has won FDA approval for Pyrukynd (mitapivat), its oral treatment for hemolytic anemia in patients with pyruvate kinase deficiency. Long-term extension data presented in December demonstrated that mitapivat’s clinically meaningful effects o...
Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron. ADG20 being explored in the phase 2/3 STAMP and EVADE studies for treatment and prevention of COVID-19, respectively. Studies paused for time being while protocols are amended for hi...
Volatility in trading of Adagio Therapeutics (ADGI -26.4%) is continuing today as shares have dropped significantly in early afternoon trading. Today's decline snaps a 4-day winning streak for the company. From the close of trading on Feb. 3 through Wednesday's close, shares rose ~31%. Y...
Gainers: Dermata (NASDAQ:DRMA) +25%. IronNet (NYSE:IRNT) +25%. China Online Education (NYSE:COE) +25%. Greenwich LifeSciences (NASDAQ:GLSI) +25%. CleanSpark (NASDAQ:CLSK) +24%. Ebang International Holdings (NASDAQ:EBON) +22%. Lufax Holding (NYSE:LU) +22%. Vaccinex (NASDAQ:VCNX) +21%. The Vale...
Adagio Therapeutics (ADGI +13.4%) so far in 2022 is managing to do something most of its peers haven't been able to -- increase in value. With its double-digit gain today, shares are up ~24% year to date. Adagio has benefitted in large part so far this year thanks to ADG20, its mono...
Gainers Bakkt Holdings (NYSE:BKKT) +30%. Kaival Brands Innovations Group (NASDAQ:KAVL) +29%. CF Acquisition (NASDAQ:CFVIU) +21%. CF Acquisition (NASDAQ:CFVI) +19%. Origin Agritech (NASDAQ:SEED) +20%. Phunware (NASDAQ:PHUN) +19%. IceCure Medical (NASDAQ:ICCM) +17%. Peloton Interactive (NASDAQ:...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...